カテゴリ： 世界, 医療/バイオ, QYResearch

細胞周期阻害剤の世界市場インサイト・予測（～2028年）

■ 英語タイトル：Global Cell Cycle Inhibitors Market Insights, Forecast to 2028

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QY22JL3471）■ 発行会社/調査会社：QYResearch
■ 商品コード：QY22JL3471
■ 発行日：2022年7月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：112
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[細胞周期阻害剤の世界市場インサイト・予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

COVID-19のパンデミックにより、細胞周期阻害剤のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に細胞周期阻害剤の世界市場のxxx％を占める「CDK4阻害剤」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
細胞周期阻害剤の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの細胞周期阻害剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

細胞周期阻害剤のグローバル主要企業には、Sanofi、Syros Pharmaceuticals、Piramal Enterprises、Pfizer、NMS Group、G1 Therapeutics、Eli Lilly and Company、Cyclacel Pharmaceuticals、F. Hoffmann-La Roche、Regeneron Pharmaceuticals、Teva Pharmaceuticals Industries、Sanofi、Genentech、Sanofi Regeneron Pharmaceuticals、BioCAD GLOBAL、Bayer AG、Otsuka America、Amgen、ANYGENなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

細胞周期阻害剤市場は、種類と用途によって区分されます。世界の細胞周期阻害剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
CDK4阻害剤、CDK9阻害剤、CDK6阻害剤、その他

【用途別セグメント】
病院、専門クリニック、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 細胞周期阻害剤製品概要
- 種類別市場（CDK4阻害剤、CDK9阻害剤、CDK6阻害剤、その他）
- 用途別市場（病院、専門クリニック、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の細胞周期阻害剤販売量予測2017-2028
- 世界の細胞周期阻害剤売上予測2017-2028
- 細胞周期阻害剤の地域別販売量
- 細胞周期阻害剤の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別細胞周期阻害剤販売量
- 主要メーカー別細胞周期阻害剤売上
- 主要メーカー別細胞周期阻害剤価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（CDK4阻害剤、CDK9阻害剤、CDK6阻害剤、その他）
- 細胞周期阻害剤の種類別販売量
- 細胞周期阻害剤の種類別売上
- 細胞周期阻害剤の種類別価格
・用途別市場規模（病院、専門クリニック、その他）
- 細胞周期阻害剤の用途別販売量
- 細胞周期阻害剤の用途別売上
- 細胞周期阻害剤の用途別価格
・北米市場
- 北米の細胞周期阻害剤市場規模（種類別、用途別）
- 主要国別の細胞周期阻害剤市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの細胞周期阻害剤市場規模（種類別、用途別）
- 主要国別の細胞周期阻害剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の細胞周期阻害剤市場規模（種類別、用途別）
- 主要国別の細胞周期阻害剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の細胞周期阻害剤市場規模（種類別、用途別）
- 主要国別の細胞周期阻害剤市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの細胞周期阻害剤市場規模（種類別、用途別）
- 主要国別の細胞周期阻害剤市場規模（トルコ、サウジアラビア）
・企業情報
Sanofi、Syros Pharmaceuticals、Piramal Enterprises、Pfizer、NMS Group、G1 Therapeutics、Eli Lilly and Company、Cyclacel Pharmaceuticals、F. Hoffmann-La Roche、Regeneron Pharmaceuticals、Teva Pharmaceuticals Industries、Sanofi、Genentech、Sanofi Regeneron Pharmaceuticals、BioCAD GLOBAL、Bayer AG、Otsuka America、Amgen、ANYGEN
・産業チェーン及び販売チャネル分析
- 細胞周期阻害剤の産業チェーン分析
- 細胞周期阻害剤の原材料
- 細胞周期阻害剤の生産プロセス
- 細胞周期阻害剤の販売及びマーケティング
- 細胞周期阻害剤の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 細胞周期阻害剤の産業動向
- 細胞周期阻害剤のマーケットドライバー
- 細胞周期阻害剤の課題
- 細胞周期阻害剤の阻害要因
・主な調査結果

Cell cycle inhibitors basically interrupt the growth proteins in order to slow or even stop the progression of the cell cycle. Cell cycle arrest can be induced at any point during the cell cycle, slowing cell division and reducing the number of actively cycling cells. The cell cycle inhibitors aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body and generally make the process slower or completely stop the cell division.
Market Analysis and Insights: Global Cell Cycle Inhibitors Market
The global Cell Cycle Inhibitors market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, CDK4 Inhibitors accounting for % of the Cell Cycle Inhibitors global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Cell Cycle Inhibitors market size is valued at US$ million in 2021, while the North America and Europe Cell Cycle Inhibitors are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cell Cycle Inhibitors landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cell Cycle Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cell Cycle Inhibitors market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cell Cycle Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cell Cycle Inhibitors market.
Global Cell Cycle Inhibitors Scope and Market Size
Cell Cycle Inhibitors market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Cell Cycle Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
CDK4 Inhibitors
CDK9 Inhibitors
CDK6 Inhibitors
Others
Segment by Application
Hospitals
Specialty Clinics
Others
By Company
Sanofi
Syros Pharmaceuticals
Piramal Enterprises
Pfizer
NMS Group
G1 Therapeutics
Eli Lilly and Company
Cyclacel Pharmaceuticals
F. Hoffmann-La Roche
Regeneron Pharmaceuticals
Teva Pharmaceuticals Industries
Sanofi
Genentech
Sanofi Regeneron Pharmaceuticals
BioCAD GLOBAL
Bayer AG
Otsuka America
Amgen
ANYGEN
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

*** レポート目次（コンテンツ）***

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell Cycle Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 CDK4 Inhibitors
1.2.3 CDK9 Inhibitors
1.2.4 CDK6 Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Cell Cycle Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cell Cycle Inhibitors Market Perspective (2017-2028)
2.2 Cell Cycle Inhibitors Growth Trends by Region
2.2.1 Cell Cycle Inhibitors Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Cell Cycle Inhibitors Historic Market Size by Region (2017-2022)
2.2.3 Cell Cycle Inhibitors Forecasted Market Size by Region (2023-2028)
2.3 Cell Cycle Inhibitors Market Dynamics
2.3.1 Cell Cycle Inhibitors Industry Trends
2.3.2 Cell Cycle Inhibitors Market Drivers
2.3.3 Cell Cycle Inhibitors Market Challenges
2.3.4 Cell Cycle Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell Cycle Inhibitors Players by Revenue
3.1.1 Global Top Cell Cycle Inhibitors Players by Revenue (2017-2022)
3.1.2 Global Cell Cycle Inhibitors Revenue Market Share by Players (2017-2022)
3.2 Global Cell Cycle Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell Cycle Inhibitors Revenue
3.4 Global Cell Cycle Inhibitors Market Concentration Ratio
3.4.1 Global Cell Cycle Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell Cycle Inhibitors Revenue in 2021
3.5 Cell Cycle Inhibitors Key Players Head office and Area Served
3.6 Key Players Cell Cycle Inhibitors Product Solution and Service
3.7 Date of Enter into Cell Cycle Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell Cycle Inhibitors Breakdown Data by Type
4.1 Global Cell Cycle Inhibitors Historic Market Size by Type (2017-2022)
4.2 Global Cell Cycle Inhibitors Forecasted Market Size by Type (2023-2028)
5 Cell Cycle Inhibitors Breakdown Data by Application
5.1 Global Cell Cycle Inhibitors Historic Market Size by Application (2017-2022)
5.2 Global Cell Cycle Inhibitors Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Cell Cycle Inhibitors Market Size (2017-2028)
6.2 North America Cell Cycle Inhibitors Market Size by Type
6.2.1 North America Cell Cycle Inhibitors Market Size by Type (2017-2022)
6.2.2 North America Cell Cycle Inhibitors Market Size by Type (2023-2028)
6.2.3 North America Cell Cycle Inhibitors Market Share by Type (2017-2028)
6.3 North America Cell Cycle Inhibitors Market Size by Application
6.3.1 North America Cell Cycle Inhibitors Market Size by Application (2017-2022)
6.3.2 North America Cell Cycle Inhibitors Market Size by Application (2023-2028)
6.3.3 North America Cell Cycle Inhibitors Market Share by Application (2017-2028)
6.4 North America Cell Cycle Inhibitors Market Size by Country
6.4.1 North America Cell Cycle Inhibitors Market Size by Country (2017-2022)
6.4.2 North America Cell Cycle Inhibitors Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Cell Cycle Inhibitors Market Size (2017-2028)
7.2 Europe Cell Cycle Inhibitors Market Size by Type
7.2.1 Europe Cell Cycle Inhibitors Market Size by Type (2017-2022)
7.2.2 Europe Cell Cycle Inhibitors Market Size by Type (2023-2028)
7.2.3 Europe Cell Cycle Inhibitors Market Share by Type (2017-2028)
7.3 Europe Cell Cycle Inhibitors Market Size by Application
7.3.1 Europe Cell Cycle Inhibitors Market Size by Application (2017-2022)
7.3.2 Europe Cell Cycle Inhibitors Market Size by Application (2023-2028)
7.3.3 Europe Cell Cycle Inhibitors Market Share by Application (2017-2028)
7.4 Europe Cell Cycle Inhibitors Market Size by Country
7.4.1 Europe Cell Cycle Inhibitors Market Size by Country (2017-2022)
7.4.2 Europe Cell Cycle Inhibitors Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell Cycle Inhibitors Market Size (2017-2028)
8.2 Asia-Pacific Cell Cycle Inhibitors Market Size by Type
8.2.1 Asia-Pacific Cell Cycle Inhibitors Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Cell Cycle Inhibitors Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Cell Cycle Inhibitors Market Share by Type (2017-2028)
8.3 Asia-Pacific Cell Cycle Inhibitors Market Size by Application
8.3.1 Asia-Pacific Cell Cycle Inhibitors Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Cell Cycle Inhibitors Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Cell Cycle Inhibitors Market Share by Application (2017-2028)
8.4 Asia-Pacific Cell Cycle Inhibitors Market Size by Region
8.4.1 Asia-Pacific Cell Cycle Inhibitors Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Cell Cycle Inhibitors Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Cell Cycle Inhibitors Market Size (2017-2028)
9.2 Latin America Cell Cycle Inhibitors Market Size by Type
9.2.1 Latin America Cell Cycle Inhibitors Market Size by Type (2017-2022)
9.2.2 Latin America Cell Cycle Inhibitors Market Size by Type (2023-2028)
9.2.3 Latin America Cell Cycle Inhibitors Market Share by Type (2017-2028)
9.3 Latin America Cell Cycle Inhibitors Market Size by Application
9.3.1 Latin America Cell Cycle Inhibitors Market Size by Application (2017-2022)
9.3.2 Latin America Cell Cycle Inhibitors Market Size by Application (2023-2028)
9.3.3 Latin America Cell Cycle Inhibitors Market Share by Application (2017-2028)
9.4 Latin America Cell Cycle Inhibitors Market Size by Country
9.4.1 Latin America Cell Cycle Inhibitors Market Size by Country (2017-2022)
9.4.2 Latin America Cell Cycle Inhibitors Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell Cycle Inhibitors Market Size (2017-2028)
10.2 Middle East & Africa Cell Cycle Inhibitors Market Size by Type
10.2.1 Middle East & Africa Cell Cycle Inhibitors Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Cell Cycle Inhibitors Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Cell Cycle Inhibitors Market Share by Type (2017-2028)
10.3 Middle East & Africa Cell Cycle Inhibitors Market Size by Application
10.3.1 Middle East & Africa Cell Cycle Inhibitors Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Cell Cycle Inhibitors Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Cell Cycle Inhibitors Market Share by Application (2017-2028)
10.4 Middle East & Africa Cell Cycle Inhibitors Market Size by Country
10.4.1 Middle East & Africa Cell Cycle Inhibitors Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Cell Cycle Inhibitors Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Cell Cycle Inhibitors Introduction
11.1.4 Sanofi Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.1.5 Sanofi Recent Developments
11.2 Syros Pharmaceuticals
11.2.1 Syros Pharmaceuticals Company Details
11.2.2 Syros Pharmaceuticals Business Overview
11.2.3 Syros Pharmaceuticals Cell Cycle Inhibitors Introduction
11.2.4 Syros Pharmaceuticals Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.2.5 Syros Pharmaceuticals Recent Developments
11.3 Piramal Enterprises
11.3.1 Piramal Enterprises Company Details
11.3.2 Piramal Enterprises Business Overview
11.3.3 Piramal Enterprises Cell Cycle Inhibitors Introduction
11.3.4 Piramal Enterprises Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.3.5 Piramal Enterprises Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Cell Cycle Inhibitors Introduction
11.4.4 Pfizer Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.4.5 Pfizer Recent Developments
11.5 NMS Group
11.5.1 NMS Group Company Details
11.5.2 NMS Group Business Overview
11.5.3 NMS Group Cell Cycle Inhibitors Introduction
11.5.4 NMS Group Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.5.5 NMS Group Recent Developments
11.6 G1 Therapeutics
11.6.1 G1 Therapeutics Company Details
11.6.2 G1 Therapeutics Business Overview
11.6.3 G1 Therapeutics Cell Cycle Inhibitors Introduction
11.6.4 G1 Therapeutics Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.6.5 G1 Therapeutics Recent Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Cell Cycle Inhibitors Introduction
11.7.4 Eli Lilly and Company Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.7.5 Eli Lilly and Company Recent Developments
11.8 Cyclacel Pharmaceuticals
11.8.1 Cyclacel Pharmaceuticals Company Details
11.8.2 Cyclacel Pharmaceuticals Business Overview
11.8.3 Cyclacel Pharmaceuticals Cell Cycle Inhibitors Introduction
11.8.4 Cyclacel Pharmaceuticals Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.8.5 Cyclacel Pharmaceuticals Recent Developments
11.9 F. Hoffmann-La Roche
11.9.1 F. Hoffmann-La Roche Company Details
11.9.2 F. Hoffmann-La Roche Business Overview
11.9.3 F. Hoffmann-La Roche Cell Cycle Inhibitors Introduction
11.9.4 F. Hoffmann-La Roche Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.9.5 F. Hoffmann-La Roche Recent Developments
11.10 Regeneron Pharmaceuticals
11.10.1 Regeneron Pharmaceuticals Company Details
11.10.2 Regeneron Pharmaceuticals Business Overview
11.10.3 Regeneron Pharmaceuticals Cell Cycle Inhibitors Introduction
11.10.4 Regeneron Pharmaceuticals Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.10.5 Regeneron Pharmaceuticals Recent Developments
11.11 Teva Pharmaceuticals Industries
11.11.1 Teva Pharmaceuticals Industries Company Details
11.11.2 Teva Pharmaceuticals Industries Business Overview
11.11.3 Teva Pharmaceuticals Industries Cell Cycle Inhibitors Introduction
11.11.4 Teva Pharmaceuticals Industries Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.11.5 Teva Pharmaceuticals Industries Recent Developments
11.12 Sanofi
11.12.1 Sanofi Company Details
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Cell Cycle Inhibitors Introduction
11.12.4 Sanofi Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.12.5 Sanofi Recent Developments
11.13 Genentech
11.13.1 Genentech Company Details
11.13.2 Genentech Business Overview
11.13.3 Genentech Cell Cycle Inhibitors Introduction
11.13.4 Genentech Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.13.5 Genentech Recent Developments
11.14 Sanofi Regeneron Pharmaceuticals
11.14.1 Sanofi Regeneron Pharmaceuticals Company Details
11.14.2 Sanofi Regeneron Pharmaceuticals Business Overview
11.14.3 Sanofi Regeneron Pharmaceuticals Cell Cycle Inhibitors Introduction
11.14.4 Sanofi Regeneron Pharmaceuticals Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.14.5 Sanofi Regeneron Pharmaceuticals Recent Developments
11.15 BioCAD GLOBAL
11.15.1 BioCAD GLOBAL Company Details
11.15.2 BioCAD GLOBAL Business Overview
11.15.3 BioCAD GLOBAL Cell Cycle Inhibitors Introduction
11.15.4 BioCAD GLOBAL Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.15.5 BioCAD GLOBAL Recent Developments
11.16 Bayer AG
11.16.1 Bayer AG Company Details
11.16.2 Bayer AG Business Overview
11.16.3 Bayer AG Cell Cycle Inhibitors Introduction
11.16.4 Bayer AG Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.16.5 Bayer AG Recent Developments
11.17 Otsuka America
11.17.1 Otsuka America Company Details
11.17.2 Otsuka America Business Overview
11.17.3 Otsuka America Cell Cycle Inhibitors Introduction
11.17.4 Otsuka America Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.17.5 Otsuka America Recent Developments
11.18 Amgen
11.18.1 Amgen Company Details
11.18.2 Amgen Business Overview
11.18.3 Amgen Cell Cycle Inhibitors Introduction
11.18.4 Amgen Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.18.5 Amgen Recent Developments
11.19 ANYGEN
11.19.1 ANYGEN Company Details
11.19.2 ANYGEN Business Overview
11.19.3 ANYGEN Cell Cycle Inhibitors Introduction
11.19.4 ANYGEN Revenue in Cell Cycle Inhibitors Business (2017-2022)
11.19.5 ANYGEN Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のインターロイキン阻害剤市場2022年：市場規模予測（～2028年）
  • 食品用腐食防止剤の世界市場インサイト・予測（～2028年）
  • 世界のPan-FGFR阻害剤市場2022年：市場規模予測（～2028年）
  • 細胞分裂タンパク質FtsZの世界市場2023年：Dardarin、LRRK2、EC2.7.11.1
  • エンジンオイル腐食防止剤の世界市場インサイト・予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QY22JL3471 )"細胞周期阻害剤の世界市場インサイト・予測（～2028年）" (英文：Global Cell Cycle Inhibitors Market Insights, Forecast to 2028)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。